Company news

Imunon, Inc. news in 2026

Imunon, Inc.'s news releases, calls and decks from 2026, newest first.

View company

IMUNON to Hold Third Quarter 2026 Financial Results and Business Update Conference Call on Thursday, November 12, 2026

November 2, 2026

IMUNON Announces Strategic Sale of ThermoDox®

October 21, 2026

IMUNON to Participate in Upcoming Investor Conferences

October 8, 2026

IMUNON Converts $1.2 Million of Debt-to-Equity

September 29, 2026

IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review

September 22, 2026

IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001

September 10, 2026

IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress

September 9, 2026

IMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001

August 26, 2026

IMUNON Reports Second Quarter 2026 Financial Results and Provides Business Update

August 11, 2026

IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer

July 30, 2026

IMUNON to Present IMNN-001 Data at Inaugural AACR Conference on Drug Discovery and Development

July 23, 2026

IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer

July 21, 2026

IMUNON Announces Data Monitoring Committee Recommends Continuation of Phase 3 OVATION 3 Study Without Modification

June 22, 2026

IMUNON to Present at the Life Sciences Investor Forum on June 25th

June 22, 2026

IMUNON Announces Up to $10 Million Cash Financing

June 3, 2026

IMUNON Reports First Quarter 2026 Financial Results and Provides Business Update

May 12, 2026

IMUNON to Hold First Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, May 12, 2026

May 5, 2026

IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study

March 30, 2026

IMUNON Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian Cancer

March 24, 2026

IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026

March 23, 2026

IMUNON sharpens focus on its promising pivotal Phase 3 ovarian cancer Study

February 5, 2026

Calls in 2026

Decks in 2026